Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
about
Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve injury: a time-course studyCapnellene, a natural marine compound derived from soft coral, attenuates chronic constriction injury-induced neuropathic pain in ratsInvolvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyroneDiscovery of prostamide F2α and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitabilityActivation of EP4 receptors contributes to prostaglandin E2-mediated stimulation of renal sensory nervesCobalamin (vitamin B12)-deficiency-induced changes in the proteome of rat cerebrospinal fluidNerve growth factor mediates a switch in intracellular signaling for PGE2-induced sensitization of sensory neurons from protein kinase A to EpacEarly vasodilator response to anodal current application in human is not impaired by cyclooxygenase-2 blockade.A pyridinium derivative from Red Sea soft corals inhibited voltage-activated potassium conductances and increased excitability of rat cultured sensory neuronesThe nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged swordRole of prostaglandins in spinal transmission of the exercise pressor reflex in decerebrated rats.Sustained morphine treatment augments prostaglandin E2-evoked calcitonin gene-related peptide release from primary sensory neurons in a PKA-dependent manner.Pharmacogenetics of new analgesics.Anti-inflammatory and antinociceptive activity of ouabain in mice.Glucocorticoid-induced leucine zipper (GILZ) over-expression in T lymphocytes inhibits inflammation and tissue damage in spinal cord injury.Anti-inflammatory and antinociceptive effects of salbutamol on acute and chronic models of inflammation in rats: involvement of an antioxidant mechanism.Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.Biological activity of plant extracts: novel analgesic drugs.Targeting invading macrophage-derived PGE2, IL-6 and calcitonin gene-related peptide in injured nerve to treat neuropathic pain.Peripheral and central mechanisms of visceral sensitization in man.Inflammatory mediators modulating the transient receptor potential vanilloid 1 receptor: therapeutic targets to treat inflammatory and neuropathic pain.Transcutaneous electrical nerve stimulation attenuates CFA-induced hyperalgesia and inhibits spinal ERK1/2-COX-2 pathway activation in rats.Teleantagonism: A pharmacodynamic property of the primary nociceptive neuron.COX2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice.Neuronal prostaglandin E2 receptor subtype EP3 mediates antinociception during inflammation.Effect of Electroacupuncture Intervention on Expression of CGRP, SP, COX-1, and PGE2 of Dorsal Portion of the Cervical Spinal Cord in Rats with Neck-Incision Pain.Consequences of altered eicosanoid patterns for nociceptive processing in mPGES-1-deficient miceActivation of the prostaglandin system in response to sleep loss in healthy humans: potential mediator of increased spontaneous painAntinociceptive actions of honokiol and magnolol on glutamatergic and inflammatory painIncreased interleukin-1α and prostaglandin E2 expression in the spinal cord at 1 day after painful facet joint injury: evidence of early spinal inflammation.Constitutive cyclooxygenase-2 is involved in central nociceptive processes in humans.Interaction between maropitant and carprofen on sparing of the minimum alveolar concentration for blunting adrenergic response (MAC-BAR) of sevoflurane in dogs.Targeting pain mediators induced by injured nerve-derived COX2 and PGE2 to treat neuropathic pain.Ibuprofen: from invention to an OTC therapeutic mainstay.Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine.Osteoarthritis of the hand II: chemistry, pharmacokinetics and pharmacodynamics of naproxen, and clinical outcome studies.Targeting cell surface trafficking of pain-facilitating receptors to treat chronic pain conditions.Vitamin A active metabolite, all-trans retinoic acid, induces spinal cord sensitization. I. Effects after oral administration.NSAIDs, Opioids, Cannabinoids and the Control of Pain by the Central Nervous System.Intrathecal betamethasone pain relief in cancer patients with vertebral metastasis: a pilot study.
P2860
Q21261389-DC9B957A-A7A4-4286-AA05-E6A138436C20Q24649995-B3D5E804-5D60-4D9E-8B86-0216FF1A9F2CQ28293158-2BEE6522-2A59-4346-8695-99D21C3D4362Q28480988-07C97E43-7F7A-4A9B-9D03-171075662822Q28566090-3F9C25A9-C67B-42C5-B16C-9131A39D55C8Q28581076-3B2EC95D-1548-41E9-8EDC-CC5C24C6486AQ28581578-57E40620-B9CB-47B6-AE87-C6FEC0F9D881Q31131984-34EE151F-C8CE-44A1-B03A-44E5BD3670D8Q33249076-AD4AB253-AA43-4924-B22D-DD0D0FF160B9Q34157706-3445EA9D-ACAC-41AD-857C-39D2CCDC3E55Q34183893-FF98B1CC-E3A4-4CB4-BAE0-19D0E75B34FFQ34204447-B8F7B60A-773F-4386-B2CB-D5A9B736083BQ35005640-D8597026-9B2A-412B-8B69-7EAA6EE0F58BQ35104707-26E11CEE-060E-4812-9A4C-F2D3117CFABEQ35729623-FCF6A661-DB20-4872-98B9-6021B1D952EBQ35991170-794CFD1B-57BD-4362-9C1C-65339BA32BC4Q36021827-2A35D594-697A-4ADB-9881-68F126757D0BQ36179675-21704157-0F6F-49A4-8B9D-70D019CDDD83Q36539465-DC0D4626-9FAD-4F58-BC45-612C02A2FB44Q36728925-80B772A0-01AE-4906-B522-6E983C6D90C1Q36734927-31822466-9376-4132-B619-3C63BC0858FFQ36945606-C2669246-C7EB-4194-9221-B746E817772EQ37039381-8616B2F8-871C-4B04-8FE0-F33AB3DB143EQ37073724-2C8252BF-5002-426F-8C73-9EA15987A5B7Q37104086-19E58ACB-20E2-4253-85FD-DCD56EC3CEB3Q37177965-34845653-313A-437E-9B9A-A809FF62854BQ37293881-6AF65DC1-C55D-42B9-B538-A3086D99CAB2Q37331891-4B0170C3-D4D9-4217-842A-37F7D3E7C383Q37396659-138DE576-F543-4AF3-88C1-2C0B1B869A95Q37624813-49D5ED85-3F16-4A3F-8D79-6259EAE69DA2Q37699479-A446359D-3AC4-4951-BC6F-413F43157F06Q37740081-A71E5C65-E29B-4A57-8BB0-91DCB249146BQ38004081-F39EF007-8419-47E4-AE17-AA69F7741571Q38060825-0D2BB5E0-0177-40EF-B565-E33477495524Q38129436-0C037D88-DCF3-4694-A3CF-B648C02F0068Q38157117-27821211-EAD9-440E-AFE9-9D564BF9A7A3Q38186775-60375116-2302-4335-8DC9-55D365E12B20Q38961105-F4C89D7B-28F3-4A35-91C2-B7F0E010EC81Q38974282-FE8C7DDF-4A1F-4B65-82D4-8B59D211F3C2Q39337922-71564D2C-5B6D-42E9-BC2E-7147E8D25D15
P2860
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
@ast
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
@en
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
@nl
type
label
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
@ast
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
@en
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
@nl
prefLabel
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
@ast
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
@en
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
@nl
P1476
Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord.
@en
P2093
Schaible HG
P304
P356
10.1016/S0301-0082(00)00063-0
P577
2001-07-01T00:00:00Z